KR20230157439A - 에스트로겐 수용체 조절제 - Google Patents
에스트로겐 수용체 조절제 Download PDFInfo
- Publication number
- KR20230157439A KR20230157439A KR1020237035079A KR20237035079A KR20230157439A KR 20230157439 A KR20230157439 A KR 20230157439A KR 1020237035079 A KR1020237035079 A KR 1020237035079A KR 20237035079 A KR20237035079 A KR 20237035079A KR 20230157439 A KR20230157439 A KR 20230157439A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- amino
- methyl
- halogen atom
- alkylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110277849 | 2021-03-15 | ||
| CN202110277849.3 | 2021-03-15 | ||
| PCT/CN2022/080680 WO2022194096A1 (zh) | 2021-03-15 | 2022-03-14 | 雌激素受体调节剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230157439A true KR20230157439A (ko) | 2023-11-16 |
Family
ID=83246765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237035079A Pending KR20230157439A (ko) | 2021-03-15 | 2022-03-14 | 에스트로겐 수용체 조절제 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240217988A1 (https=) |
| EP (1) | EP4310079A4 (https=) |
| JP (2) | JP7605536B2 (https=) |
| KR (1) | KR20230157439A (https=) |
| CN (2) | CN115073493B (https=) |
| AU (1) | AU2022240650B2 (https=) |
| WO (1) | WO2022194096A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7605536B2 (ja) * | 2021-03-15 | 2024-12-24 | 深▲せん▼福沃薬業有限公司 | エストロゲン受容体モジュレーター |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| WO2012142029A2 (en) * | 2011-04-10 | 2012-10-18 | Florida A&M University | Serms for the treatment of estrogen receptor-mediated disorders |
| CN104910137B (zh) * | 2014-03-10 | 2017-04-19 | 山东轩竹医药科技有限公司 | Cdk激酶抑制剂 |
| KR20180012853A (ko) * | 2015-06-16 | 2018-02-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도 |
| US9969732B2 (en) | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| US10125135B2 (en) * | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
| WO2018138739A1 (en) * | 2017-01-27 | 2018-08-02 | Sun Pharma Advanced Research Company Limited | Novel antiestrogenic heterocyclic compounds |
| WO2019192533A1 (zh) * | 2018-04-04 | 2019-10-10 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| TW202003495A (zh) * | 2018-05-23 | 2020-01-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 苯並哌啶或雜芳基並哌啶類衍生物、其製備方法及其在醫藥上的應用 |
| JP7605536B2 (ja) * | 2021-03-15 | 2024-12-24 | 深▲せん▼福沃薬業有限公司 | エストロゲン受容体モジュレーター |
-
2022
- 2022-03-14 JP JP2023557230A patent/JP7605536B2/ja active Active
- 2022-03-14 KR KR1020237035079A patent/KR20230157439A/ko active Pending
- 2022-03-14 CN CN202210249231.0A patent/CN115073493B/zh active Active
- 2022-03-14 AU AU2022240650A patent/AU2022240650B2/en active Active
- 2022-03-14 CN CN202510027136.XA patent/CN119930646A/zh active Pending
- 2022-03-14 US US18/282,147 patent/US20240217988A1/en active Pending
- 2022-03-14 WO PCT/CN2022/080680 patent/WO2022194096A1/zh not_active Ceased
- 2022-03-14 EP EP22770451.7A patent/EP4310079A4/en active Pending
-
2024
- 2024-12-05 JP JP2024212569A patent/JP2025023300A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4310079A1 (en) | 2024-01-24 |
| AU2022240650A1 (en) | 2023-10-19 |
| US20240217988A1 (en) | 2024-07-04 |
| EP4310079A4 (en) | 2024-10-30 |
| CN115073493B (zh) | 2024-12-10 |
| JP7605536B2 (ja) | 2024-12-24 |
| WO2022194096A1 (zh) | 2022-09-22 |
| CN115073493A (zh) | 2022-09-20 |
| JP2024511044A (ja) | 2024-03-12 |
| JP2025023300A (ja) | 2025-02-14 |
| AU2022240650B2 (en) | 2025-01-30 |
| CN119930646A (zh) | 2025-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102614939B1 (ko) | 피리미딘-융합고리 화합물 및 그의 제조방법과 용도 | |
| KR102384139B1 (ko) | 탈유비퀴틴화 효소(dub) 억제제로서 스피로-축합된 피롤리딘 유도체 | |
| AU2019327475B2 (en) | INHIBITING αV β6 INTEGRIN | |
| ES2902050T3 (es) | Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1 | |
| KR102605460B1 (ko) | αvβ6 인테그린 억제제 | |
| CA3229646A1 (en) | Irak4 degradation agent, and preparation method therefor and use thereof | |
| JP6581111B2 (ja) | Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体 | |
| JP2022539579A (ja) | Ｐｌｋ１の選択的分解誘導化合物 | |
| CN109496213B (zh) | 螺环化合物及其制备和使用方法 | |
| KR20120052343A (ko) | 융합된 아미노디하이드로피리미돈 유도체 | |
| KR20100103702A (ko) | 축합 아미노디하이드로 티아진 유도체 | |
| TW202237597A (zh) | 新型egfr降解劑 | |
| CN117412964A (zh) | 取代的杂环化合物及其应用 | |
| CN116478145B (zh) | Alk2激酶抑制剂 | |
| KR20230157439A (ko) | 에스트로겐 수용체 조절제 | |
| KR20250004826A (ko) | 암 치료에서의 egfr 저해제 | |
| HK40106742A (en) | Estrogen receptor antagonist | |
| CN112661751B (zh) | 作为bcl-2抑制剂的杂环化合物 | |
| EP3345909B1 (en) | Tetrahydrooxepinopyridine compound | |
| WO2026039844A1 (en) | Stat6 degraders and uses thereof | |
| CN121226391A (zh) | 一种杂环化合物及其组合物和应用 | |
| KR20220119088A (ko) | Kras 돌연변이체 단백질 억제제 | |
| CN121263412A (zh) | 用于雄激素受体依赖性疾病的苯并(杂)环烷基化合物 | |
| JP2024537939A (ja) | ジオキサジン及びｇｂａ関連疾患の治療におけるその使用 | |
| CN121293199A (zh) | 酪氨酸激酶2降解化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |